When does soreness need an exam before blood or marrow care?

Which warning signs can't wait for an office visit?

An injured joint that looks bent or won't hold weight needs prompt care. Fever with heat, redness, and swelling may mean an infection. Calf swelling or redness after a procedure can warn of a blood clot. Don't wait for a regular visit with these signs.

A weak foot, lost feeling, or back pain with bladder trouble needs quick help. Bowel trouble with those changes also calls for urgent care. Night pain with weight loss deserves an exam as well. Tell the doctor about every warning sign directly.

What happens during a planned joint exam?

The doctor asks where the ache began and which motions change it. The exam checks swelling, strength, sore spots, and movement. An X-ray may show wear or injury. You'll also name the chores that soreness has made harder.

Take the names of every medicine you use to the visit. Mention bleeding trouble, infection, or active cancer care before any procedure. Don't stop a blood-thinning drug without direction from its doctor. This health history helps rule out unsafe choices.

How can you tell whether a procedure fits?

The exam must first point to a likely cause for your soreness. Then the doctor can compare self-care, physical therapy, procedures, or surgery. Ask about risks when the provider takes blood or marrow from you. Learn which number to call if trouble begins afterward.

Until the visit, avoid the motion that causes sharp pain. Gentle movement often works better than holding the joint still for hours. Stop if swelling or soreness rises quickly. At QC Kinetix, joint preservation includes regenerative treatments: medical providers may prepare your blood or marrow for use near the joint to try easing soreness.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

4. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.